Source: Sarepta Therapeutics, Inc.Media and Investors:Sarepta Therapeutics, Inc.Ian Estepan, 617-274-4052iestepan@sarepta.comorW2O GroupBrian Reid, 212-257-6725breid@w2ogroup.comGenethonStéphanie BARDON - +331. Genethon's micro-dystrophin gene therapy approach can target the majority of patients with DMD. "Microdystrophin-based gene therapy is a very promising approach with potential application to a large majority of Duchenne patients. "This partnership brings together our collective experience in Duchenne drug development and Genethon's particular expertise in gene therapy for rare diseases. YposKesi employs approximately 150 experts in bio-production at its current 54,000 square feet manufacturing facility, and plans significant future expansion to meet the growing demand of gene therapy products.
Mayo Clinic Ventures funds new cancer-fighting cell, gene therapy
W winds shifting to N at 10 to 20 mph. Winds WNW at 10 to 15 mph. Chance of rain 100%. Rochester, MN (55903)TodayScattered thunderstorms in the morning becoming more widespread in the afternoon. Chance of rain 90%..TonightThunderstorms during the evening, then partly cloudy overnight.collected by :Lucy William
No comments:
Post a Comment